Our results are in agreement with previous ones that reported that not only MDS patients display over-expression of CD200 on CD33+ bone marrow cells, but also CD200 expression was significantly associated with high risk MDS subtype being higher in high risk group as compared to intermediate risk group. The gene discussed is CD33; the disease is myelodysplastic syndrome.